Eli Lilly and Co (LLY.N)
54.92USD
4:00pm EDT
$-0.22 (-0.40%)
$55.14
$55.35
$56.05
$54.67
1,314,542
1,222,125
$58.40
$39.93
LLY.N
About
Overall
| Beta: | 0.72 |
| Market Cap (Mil.): | $62,118.60 |
| Shares Outstanding (Mil.): | 1,126.56 |
| Dividend: | 0.49 |
| Yield (%): | 3.55 |
Financials
| LLY.N | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | 13.22 | 34.93 | 35.13 |
| EPS (TTM): | 4.17 | -- | -- |
| ROI: | 18.36 | 19.47 | 18.83 |
| ROE: | 31.06 | 20.22 | 19.68 |
Lilly CEO recovering after repair to aorta
- John Lechleiter, the longtime chief executive of Eli Lilly and Co, is recovering from successful surgery to repair a dilated aorta, the U.S. drugmaker said on Tuesday.
UPDATE 1-Eli Lilly lymphoma drug fails in late-stage trial
May 10 - Eli Lilly and Co said it will end development of an experimental cancer drug after it failed in a late-stage trial to delay a worsening of symptoms in patients with lymphoma.
Lilly CEO Lechleiter to undergo surgery for dilated aorta
- Drug maker Eli Lilly and Co said Chief Executive John Lechleiter will undergo a surgery on May 13 to treat a dilated aorta but is expected to recover and return to work by this summer.
Lilly profit beats forecast, helped by lower taxes
- Eli Lilly and Co on Wednesday reported higher-than-expected first-quarter earnings, helped by favorable taxes and higher sales of its treatments for diabetes, depression and lung cancer.
Lilly profit beats forecast
April 24 - Eli Lilly and Co on Wednesday reported higher-than-expected first-quarter earnings, helped by sales of its treatments for diabetes, depression and lung cancer.
UPDATE 1-Lilly diabetes drug as good as insulin in study
* Drug also showed benefits when used with other treatments
Lilly confident on keeping dividend through patent cliff
BRUSSELS - Eli Lilly and Co will maintain its dividend despite the erosion of its earnings by generic copies of blockbuster drugs and should be well placed by the end of 2013 to assess the potential of its future medicines, its chief executive said.
Eli Lilly CEO says company keeping animal health business
NEW YORK - Eli Lilly and Co's chief executive said his company had no intention of following Pfizer's lead by spinning off or selling the company's lucrative Elanco animal health unit.
Eli Lilly CEO says company keeping animal health business
* Believes amyloid plaques best target for Alzheimer's drugs
UPDATE 2-U.S. Medicare panel skeptical of brain-plaque scans
Jan 30 - A Medicare advisory panel expressed skepticism on Wednesday that radioactive imaging agents like Eli Lilly and Co's Amyvid can improve health outcomes of people with early symptoms of memory problems.
Competitors
| Price | Change | |
|---|---|---|
| Pfizer Inc. (PFE.N) | $29.30 | +0.52 |
| GlaxoSmithKline plc (GSK.L) | 1,773.00p | +31.00 |
| Novartis AG (NOVN.VX) | CHF73.65 | +1.25 |
| Merck & Co., Inc. (MRK.N) | $46.71 | -0.62 |
| Abbott Laboratories (ABT.N) | $37.72 | 0.00 |
| Bristol Myers Squibb Co. (BMY.N) | $46.40 | +2.34 |
| Bristol Myers Squibb Co. (BMY_p.N) | $567.60 | 0.00 |
| AstraZeneca plc (AZN.L) | 3,485.50p | +91.00 |
| Sanofi SA (SASY.PA) | €86.43 | +1.29 |
| Amgen, Inc. (AMGN.OQ) | $104.53 | +0.29 |
Earnings vs. 
Estimates
Analyst Research Reports
| Report Title | Price |
|---|---|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
|
Trading Report for (LLY). A detailed report, including free correlated market analysis, and updates.
Provider: Stock Traders Daily
|
$58.00
|
|
Provider: GlobalData
|
$250.00
|
|
Provider: Stock Traders Daily
|
$495.00
|
|
Provider: Market Edge
|
$10.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
